000182439 001__ 182439
000182439 005__ 20240229145719.0
000182439 0247_ $$2doi$$a10.1186/s13643-022-02105-0
000182439 0247_ $$2pmid$$apmid:36329524
000182439 0247_ $$2altmetric$$aaltmetric:138038539
000182439 037__ $$aDKFZ-2022-02648
000182439 041__ $$aEnglish
000182439 082__ $$a610
000182439 1001_ $$aFuchs, Juri$$b0
000182439 245__ $$aGenerating evidence for diagnosis and therapy of RarE LIVEr disease: the RELIVE Initiative for systematic reviews and meta-analyses.
000182439 260__ $$aLondon$$bBiomed Central$$c2022
000182439 3367_ $$2DRIVER$$aarticle
000182439 3367_ $$2DataCite$$aOutput Types/Journal article
000182439 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1667814880_20813$$xReview Article
000182439 3367_ $$2BibTeX$$aARTICLE
000182439 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182439 3367_ $$00$$2EndNote$$aJournal Article
000182439 500__ $$aCommentary
000182439 520__ $$aRare liver lesions and diseases have seldomly aroused major interest of researchers. For most guidelines, presumably similar clinical conditions are pooled without detailed investigations of singularities that they present.A multidisciplinary project aiming to establish evidence-based therapies for rare liver diseases has been founded. A series of systematic reviews and meta-analyses will be the starting point for a structured development of guidelines for rare conditions of the liver affecting pediatric and adult populations. The novel approach will be focusing on case reports and small patient series with distinct rare liver diseases without pooling several presumably acceptably similar conditions. Thus, a vital resource of information will be utilized, which has been largely neglected hitherto.Highly specific recommendations based on highest available evidence will therefore be developed for specific conditions, advancing the individualized medicine approach for the afflicted patients.
000182439 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000182439 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182439 650_7 $$2Other$$aEvidence-based medicine
000182439 650_7 $$2Other$$aMeta-analysis
000182439 650_7 $$2Other$$aRELIVE
000182439 650_7 $$2Other$$aRare liver disease
000182439 650_7 $$2Other$$aRare liver tumors
000182439 650_7 $$2Other$$aSystematic reviews
000182439 7001_ $$aMurtha-Lemekhova, Anastasia$$b1
000182439 7001_ $$aPfeiffenberger, Jan$$b2
000182439 7001_ $$aFichtner, Alexander$$b3
000182439 7001_ $$aGünther, Patrick$$b4
000182439 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b5$$udkfz
000182439 7001_ $$aMayer, Philipp$$b6
000182439 7001_ $$aHornuss, Daniel$$b7
000182439 7001_ $$aKlotz, Rosa$$b8
000182439 7001_ $$aProbst, Pascal$$b9
000182439 7001_ $$aHoffmann, Katrin$$b10
000182439 7001_ $$aInitiative, RELIVE$$b11$$eCollaboration Author
000182439 773__ $$0PERI:(DE-600)2662257-9$$a10.1186/s13643-022-02105-0$$gVol. 11, no. 1, p. 235$$n1$$p235$$tSystematic Reviews$$v11$$x2046-4053$$y2022
000182439 909CO $$ooai:inrepo02.dkfz.de:182439$$pVDB
000182439 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000182439 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000182439 9141_ $$y2022
000182439 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-08-29
000182439 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-29
000182439 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-29
000182439 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-29
000182439 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-29
000182439 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000182439 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000182439 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:19:49Z
000182439 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:19:49Z
000182439 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2021-02-14T16:19:49Z
000182439 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000182439 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000182439 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000182439 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000182439 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000182439 9201_ $$0I:(DE-He78)D240-20160331$$kD240$$lTranslationale Immuntherapie$$x0
000182439 980__ $$ajournal
000182439 980__ $$aVDB
000182439 980__ $$aI:(DE-He78)D240-20160331
000182439 980__ $$aUNRESTRICTED